- Home
- DSGN vs CURV Comparison
DSGN vs CURV Comparison
Compare DSGN & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CURV
- Stock Information
- Founded
- DSGN 2017
- CURV 2001
- Country
- DSGN United States
- CURV United States
- Employees
- DSGN N/A
- CURV N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CURV Clothing/Shoe/Accessory Stores
- Sector
- DSGN Health Care
- CURV Consumer Discretionary
- Exchange
- DSGN Nasdaq
- CURV Nasdaq
- Market Cap
- DSGN 208.9M
- CURV 248.6M
- IPO Year
- DSGN 2021
- CURV 2021
- Fundamental
- Price
- DSGN $5.26
- CURV $2.28
- Analyst Decision
- DSGN
- CURV Hold
- Analyst Count
- DSGN 0
- CURV 4
- Target Price
- DSGN N/A
- CURV $5.00
- AVG Volume (30 Days)
- DSGN 141.5K
- CURV 551.3K
- Earning Date
- DSGN 08-07-2025
- CURV 09-04-2025
- Dividend Yield
- DSGN N/A
- CURV N/A
- EPS Growth
- DSGN N/A
- CURV N/A
- EPS
- DSGN N/A
- CURV 0.09
- Revenue
- DSGN N/A
- CURV $1,089,931,000.00
- Revenue This Year
- DSGN N/A
- CURV N/A
- Revenue Next Year
- DSGN N/A
- CURV N/A
- P/E Ratio
- DSGN N/A
- CURV $25.19
- Revenue Growth
- DSGN N/A
- CURV N/A
- 52 Week Low
- DSGN $2.60
- CURV $2.08
- 52 Week High
- DSGN $7.77
- CURV $7.25
- Technical
- Relative Strength Index (RSI)
- DSGN 61.90
- CURV 35.57
- Support Level
- DSGN $4.68
- CURV $2.16
- Resistance Level
- DSGN $5.60
- CURV $2.35
- Average True Range (ATR)
- DSGN 0.39
- CURV 0.14
- MACD
- DSGN 0.04
- CURV 0.06
- Stochastic Oscillator
- DSGN 79.95
- CURV 36.79
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.